<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556592</url>
  </required_header>
  <id_info>
    <org_study_id>LP0162-1342</org_study_id>
    <secondary_id>2018-000534-35</secondary_id>
    <nct_id>NCT03556592</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4</brief_title>
  <official_title>An Open-label, Multi Centre Drug-drug Interaction Trial to Investigate the Effects of Tralokinumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Subjects With Moderate-to-severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate if tralokinumab changes the metabolism of
      selected CYP substrates in adults with moderate-to-severe AD after:

        -  14 weeks of treatment with tralokinumab

        -  a single dose of tralokinumab
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of the AUC-last at Week 15 (after multiple doses of tralokinumab) to that on Day -7 (at baseline) for each of the 5 substrates</measure>
    <time_frame>Day -7 and Week 15</time_frame>
    <description>AUC-last = area under the plasma concentration curve from time 0 to the last quantifiable observation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of the Cmax at Week 15 (after multiple doses of tralokinumab) to that on Day -7 (at baseline) for each of the 5 substrates</measure>
    <time_frame>Day -7 and Week 15</time_frame>
    <description>Cmax = maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of the AUC-last on Day 8 (after a single dose of tralokinumab) to that on Day -7 (at baseline) for each of the 5 substrates</measure>
    <time_frame>Day -7 and Day 8</time_frame>
    <description>AUC-last = area under the plasma concentration curve from time 0 to the last quantifiable observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of the Cmax on Day 8 (after a single dose of tralokinumab) to that on Day -7 (at baseline) for each of the 5 substrates</measure>
    <time_frame>Day -7 and Day 8</time_frame>
    <description>Cmax = maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of the AUC-inf on Day 8 (after a single dose of tralokinumab) to that on Day -7 (at baseline) for each of the 5 substrates</measure>
    <time_frame>Day -7 and Day 8</time_frame>
    <description>AUC-inf = area under the plasma concentration curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From Day 1 up to Week 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-drug antibodies (yes/no)</measure>
    <time_frame>From Day 1 up to Week 30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tralokinumab - investigational medicinal product:
Week 0: subcutaneous (SC) injection of tralokinumab loading dose.
Week 2 to Week 14: SC injection of tralokinumab maintenance dose.
CYP substrates - non-investigational medicinal products:
Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>1x 100 mg tablet</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>2x 5 mg tablets</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>1x 20 mg capsule</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>1x 100 mg tablet</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam Hydrochloride</intervention_name>
    <description>1 mL of 2 mg/mL oral solution/syrup</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and above.

          -  Diagnosis of AD as defined by the Hanifin and Rajka 1980 criteria for AD.

          -  History of AD for ≥1 year.

          -  Subjects who have a recent history of inadequate response to treatment with topical
             medications or for whom topical treatments are otherwise medically inadvisable.

          -  AD involvement of ≥10% body surface area at screening and baseline.

          -  Stable dose of emollient twice daily (or more, as needed) for at least 14 days before
             baseline.

          -  Willingness to abstain from consumption of any 1 or more of the following items in the
             periods specified:

               -  ±7 days within each cocktail dosing visit: foods/beverages that affect the CYP
                  system:

                    -  Grapefruit or grapefruit juice, Seville oranges or orange juice, starfruit,
                       pomegranate and cranberry juices, red wine, red grape extract.

                    -  Cruciferous vegetables (for example broccoli).

                    -  Chargrilled meat.

               -  ±48 hours within each cocktail dosing visit: caffeinated beverages and
                  foods/drugs that contain caffeine.

        Exclusion Criteria:

          -  Administration, within 14 days or 5 half-lives (whichever is longer) prior to Day -7,
             of any medication that is a known inducer or inhibitor of 1 or more of the following
             CYP enzymes: CYP3A, CYP2C19, CYP2C9, CYD2D6, and CYP1A2.

          -  Subjects who are poor metabolisers of CYP2C9, CYP2C19, or CYP2D6, based on genotyping.

          -  Any contraindication to 1 or more of the following drugs, according to the applicable
             labelling: caffeine, warfarin, omeprazole, metoprolol, or midazolam.

          -  Consumption of any 1 or more of the following items in the periods specified:

               -  ±7 days within each cocktail dosing visit: foods/beverages that affect the CYP
                  system:

                    -  Grapefruit or grapefruit juice, Seville oranges or orange juice, starfruit,
                       pomegranate and cranberry juices, red wine, red grape extract.

                    -  Cruciferous vegetables (for example broccoli).

                    -  Chargrilled meat.

               -  ±48 hours within each cocktail dosing visit: caffeinated beverages and
                  foods/drugs that contain caffeine.

          -  Nausea or diarrhoea 1 week prior to Day -7.

          -  Active dermatologic conditions that may confound the diagnosis of AD.

          -  Use of tanning beds or phototherapy within 5 weeks prior to Day -7.

          -  Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic
             corticosteroid within 3 weeks prior to Day -7.

          -  Treatment with topical corticosteroids, topical calcineurin inhibitors, or topical
             phosphodiesterase 4 inhibitors within 1 week prior to Day -7.

          -  Receipt of any marketed biological therapy or investigational biologic agent
             (including immunoglobulin, anti-IgE, or dupilumab):

               -  Any cell-depleting agents, including but not limited to rituximab: within 6
                  months prior to Day -7, or until lymphocyte count returns to normal, whichever is
                  longer.

               -  Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to
                  Day -7.

          -  Active skin infection within 1 week prior to Day -7.

          -  Clinically significant infection within 4 weeks prior to Day -7.

          -  A helminth parasitic infection within 6 months prior to the date informed consent is
             obtained.

          -  Tuberculosis requiring treatment within 12 months prior to screening.

          -  Known primary immunodeficiency disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

